Exome Asset Management LLC Acquires 240,108 Shares of Replimune Group, Inc. $REPL

Key Points

• Exome Asset Management LLC significantly increased its stake in Replimune Group by 438.6% in Q1, owning 294,846 shares valued at approximately $2.87 million.
• Several institutional investors also boosted their positions, with Tang Capital Management LLC growing its holdings by 125% and owning 2.7 million shares worth around $32.7 million.
• Replimune Group recently reported a loss per share of $0.95 for the quarter, missing analysts' expectations of $0.83, which could impact investor sentiment.

Exome Asset Management LLC raised its stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 438.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 294,846 shares of the company's stock after acquiring an additional 240,108 shares during the quarter. Replimune Group makes up approximately 2.4% of Exome Asset Management LLC's investment portfolio, making the stock its 16th largest position. Exome Asset Management LLC owned 0.38% of Replimune Group worth $2,875,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in REPL. Redmile Group LLC increased its position in Replimune Group by 2.6% during the 4th quarter. Redmile Group LLC now owns 4,905,527 shares of the company's stock worth $59,406,000 after purchasing an additional 124,344 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Replimune Group by 6.6% during the first quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company's stock worth $37,372,000 after buying an additional 237,185 shares during the last quarter. Tang Capital Management LLC increased its holdings in shares of Replimune Group by 125.0% during the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock worth $32,697,000 after buying an additional 1,500,000 shares in the last quarter. RTW Investments LP lifted its stake in shares of Replimune Group by 82.1% in the 4th quarter. RTW Investments LP now owns 2,065,010 shares of the company's stock valued at $25,007,000 after acquiring an additional 931,223 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of Replimune Group by 2.8% during the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company's stock valued at $11,927,000 after acquiring an additional 33,574 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Replimune Group

In related news, CFO Emily Luisa Hill sold 9,154 shares of the business's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $5.37, for a total value of $49,156.98. Following the transaction, the chief financial officer owned 134,368 shares in the company, valued at $721,556.16. The trade was a 6.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.20% of the stock is currently owned by insiders.

Replimune Group Trading Down 4.7%

REPL stock traded down $0.28 during trading on Friday, hitting $5.73. The company had a trading volume of 1,381,936 shares, compared to its average volume of 2,068,806. The business has a 50-day moving average of $6.68 and a 200-day moving average of $8.41. Replimune Group, Inc. has a one year low of $2.68 and a one year high of $17.00. The stock has a market cap of $447.28 million, a PE ratio of -1.77 and a beta of 0.51. The company has a current ratio of 6.94, a quick ratio of 6.94 and a debt-to-equity ratio of 0.21.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Research analysts predict that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on REPL. Jefferies Financial Group lowered their target price on Replimune Group from $31.00 to $6.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. BMO Capital Markets cut Replimune Group from an "outperform" rating to an "underperform" rating and reduced their price target for the stock from $27.00 to $2.00 in a report on Wednesday, July 23rd. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $9.00 price objective (down previously from $19.00) on shares of Replimune Group in a report on Tuesday, July 22nd. Leerink Partners reiterated a "market perform" rating and set a $3.00 target price (down from $21.00) on shares of Replimune Group in a research report on Tuesday, July 22nd. Finally, Barclays cut shares of Replimune Group from an "overweight" rating to an "equal weight" rating and decreased their price target for the company from $17.00 to $3.00 in a research report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $6.50.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.